by Maria Zannes | Mar 12, 2019 | Press Releases
MARCH 12, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced the formation of a Scientific and Medical Advisory (SMA) Board to provide independent expert advice and counsel on the Company’s research and development of...
by Maria Zannes | Mar 6, 2019 | Press Releases
MARCH 6, 2019 (San Antonio, TX) Healthcare innovators Lyfebulb and Helsinn selected bioAffinity Technologies, a privately held biotech company developing diagnostics and therapeutics for cancer, as one of 10 finalists for the second annual in Oncology. The Innovation...
by Maria Zannes | Mar 6, 2019 | News
BioAffinity Technologies is proud to be named a finalist in the Lyfebulb Helsinn 2019 Innovation Summit in Oncology. Lyfebulb-Helsinn Innovation Summit March 18 and 19, 2019 Monaco, Principality of Monaco Ten finalists will compete at the second annual...
by Maria Zannes | Feb 5, 2019 | Press Releases
FEBRUARY 4, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, announced that the Canadian Intellectual Property Office has awarded a patent expanding the Company’s claims associated with its proprietary CyPath© technology for the early...
